The side effects of Tasfigo succinate involve multiple systemic reactions and require differentiated management measures based on severity. The following provides a detailed description from three aspects: severe side effect classification, common adverse reaction management, and special monitoring requirements, and offers specific mitigation plans.

1. Serious side effects of Tasfigo succinate that require urgent treatment

(1) Hyperphosphatemia

When it occurs, medication should be suspended, a low phosphorus diet should be adopted, and treatment with phosphate binders should be considered until serum phosphorus concentration returns to normal levels.

(2) Retinal detachment

Immediate discontinuation of medication and referral to ophthalmology is required for blurred vision or visual field defects. It is contraindicated for those with permanent visual impairment.

2. Common side effect relief strategies for Tasfigo succinate

(1) Digestive system response

Diarrhea can be treated with oral loperamide, while for stomatitis, mouthwash containing lidocaine should be used. For nausea and vomiting, it is recommended to eat in small portions and take antiemetic medication.

(2) Skin and nail lesions

Palms and soles redness and swelling syndrome requires reducing friction and using urea ointment locally; Nail lesions should be kept dry to avoid external injuries.

(3) Hematological toxicity

When neutrophils decrease, infection should be prevented, thrombocytopenia should avoid trauma, and iron supplementation can be considered for hemoglobin reduction.

3. Management of Other Systemic Side Effects of Tasfigo Succinate

(1) Eye symptoms

Artificial tears are used for dry eye syndrome, antibiotic eye drops are required for keratitis, and medication should be suspended for severe corneal lesions.

(2) Metabolic abnormalities

Hyperuricemia requires increased water intake, and if necessary, uric acid lowering drugs should be used; If the lipase level increases by more than 3 times, the medication should be stopped.

4. Comprehensive monitoring requirements

Blood phosphorus levels will be tested every 2 weeks during baseline and medication period. Ophthalmic examinations will be conducted monthly, and blood routine monitoring will be conducted on a weekly basis. Dose adjustments will be necessary in case of toxicity levels 2 or higher.